Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094549
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2004-10-20
Brief Title:
Olanzapine vs Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goals of this study are
A To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania
B To assess the safety of olanzapine and any side effects that might be associated with it as well as the quality of life and functioning of patients treated with olanzapine
C To assess how olanzapine compares to divalproex
A To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania
B To assess the safety of olanzapine and any side effects that might be associated with it as well as the quality of life and functioning of patients treated with olanzapine
C To assess how olanzapine compares to divalproex
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-MC-HGKQ | None | None | None |